|AVEXIS, INC. filed this Form S-1 on 01/15/2016|
Table of Contents
Scientific Officer, Dr. Brian Kaspar. Dr. Kaspar has over 20 years of gene therapy experience, and is currently serving as a principal investigator in the Center for Gene
Therapy at the Research Institute at NCH. NCH is a leading pediatric gene therapy research institute.
execute on AveXis' mission, we have assembled a management team that includes individuals with expertise in gene therapy, regulatory development, product development, manufacturing
and commercialization, with a history of success in building and operating innovative biotechnology and healthcare companies focused on rare and life-threatening diseases. This team is led by our
President and Chief Executive Officer, Sean P. Nolan, who brings 24 years of broad leadership and management experience in the biopharmaceutical industry to AveXis. Most recently he was the
chief business officer of InterMune, Inc. where he led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business
development, and global manufacturing and supply chain. Our other management team members also have successful track records developing and commercializing drugs through previous experiences at
companies such as Abbott Laboratories, Amgen, Auspex, InterMune, Hospira, Novartis, Pfizer, Daiichi Sankyo and Quest Diagnostics.
have been supported by a leading group of biotech investors including funds and accounts managed by Adage Capital Management, L.P., Boxer Capital of Tavistock Life Sciences,
Deerfield Management, Foresite Capital Management, LLC, Janus Capital Management LLC, QVT Financial LP, RA Capital Management, Roche Finance Ltd, Rock Springs Capital
Management LP, RTW Investments, LLC, T. Rowe Price Associates, Inc. and Venrock.
We are building a patient-centric business with the goal of developing innovative gene therapy treatments that
transform the lives of patients and their families suffering from rare and life-threatening neurological genetic diseases. In order to accomplish this goal, we plan to execute on the following key
- Rapidly advance our SMA Type 1 program through clinical trials
in the United States. We are currently conducting an open-label, dose-escalation Phase 1 clinical trial of AVXS-101 in patients
with SMA Type 1 at NCH. As of December 31, 2015, we had fully enrolled our Phase 1 trial, having dosed a total of 15 patients in two dosing cohorts. The FDA has granted AVXS-101
orphan drug designation for the treatment of all types of SMA and fast track designation for the treatment of SMA Type 1.
- Expand the development of AVXS-101 into SMA Types 2 and
3. Based on preclinical and our preliminary clinical observations to date, we believe AVXS-101 may also have the ability to treat
patients with SMA Types 2 and 3, which result from the same genetic defect as SMA Type 1. In the United States, the incidence of SMA is approximately one in 10,000 live births
with SMA Types 1 and 2 being the most common representing approximately 60% and 27% of all cases of SMA, respectively, and SMA Type 3 being less common.
- Advance the development of AVXS-101 outside of the United
States. The incidence, standard of care and prognosis of SMA globally are generally consistent. With no approved treatments, we believe
there is significant unmet need for patients suffering from SMA outside the U.S. We intend to conduct clinical trials outside of the United States, beginning in Europe, in an effort to expand access
to AVXS-101 to patients in international markets.
- Build a pipeline of gene therapy treatments for other rare and
life-threatening neurological genetic diseases. In addition to our programs in SMA, we also intend to identify, acquire, develop and
commercialize novel product candidates for the treatment of other rare and life-threatening neurological genetic diseases with mechanisms of action that
© AveXis, Inc. All Rights Reserved.